Recent studies demonstrated that MK-0646 had a potent anti-proliferative effect in Type I and II endometrial cancer cell lines, associated with a decrease in IGF1-induced IGF1R, AKT, and ERK1/2 phosphorylation. This evidence concerns the gene MAPK3 and endometrial cancer.